Lastly, BRAF mutations, considered the most common in cutaneous melanoma and significant therapeutic targets [57], remain rare in dedifferentiated lesions, as none of the rhabdomyosarcomatous melanomas harboured this modification. This evidence concerns the gene BRAF and cutaneous melanoma.